IP Library Granted Patent US 9,314,507
Granted Patent B2
US 9,314,507 · App. 13/284,529 · Granted Apr 19, 2016

Methods of treatment of heart failure with natriuretic peptides

Inventors: Daron Evans (San Mateo, CA); Hsiao Lieu (Burlingame, CA); William P. Van Antwerp (Valencia, CA)
Assignee: Capricor Therapeutics, INC.
A61K38/2242A61K38/22C07K14/575C07K14/58
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,314,507
App. No.
13/284,529
Granted
Apr 19, 2016
Kind
B2
Abstract

Methods of treating heart failure, or decreasing blood pressure, comprising administering an NP at an appropriate dose, or in an amount sufficient to provide particular concentrations of NP, are provided.

Claims (13)

1. A method of treating a patient with heart failure comprising;

A) administering a natriuretic peptide (NP) to the patient continuously for at least 24 hours, wherein the continuous administration comprises a first dose of the NP and a second dose of the NP; and,

B) administering to the patient a vasoactive medication at a time point during the administration of the natriuretic peptide;

wherein the first dose of the NP is administered to the patient from about 2 hours before the administration of the vasoactive medication up to about 4 hours after administration of the vasoactive medication; and

wherein the second dose of the NP is administered up to about 2 hours before the administration of the vasoactive medication and about 4 hours after administration of the vasoactive medication; and,

wherein the first dose of NP is lower than the second dose of NP.

2. The method of claim 1 , wherein the heart failure is selected from the group consisting of acute heart failure, decompensated heart failure, and chronic heart failure.

3. The method of claim 1 , wherein the vasoactive medication is selected from the group consisting of statins, beta-blockers, diuretics, alpha blockers, ACE inhibitor, angiotensin receptor blocker, calcium channel blockers, furosemide, and mixtures thereof.

4. The method of claim 1 , wherein the NP is selected from the group consisting of CD-NP (cenderitide), atrial natriuretic peptide, brain natriuretic peptide, C-type natriuretic peptide, urodilatin, BD-NP, CU-NP, and mixtures thereof.

5. The method of claim 1 , wherein the first dose of the NP is administered to the patient from about 4 hours before the administration of the vasoactive medication up to about 4 hours after administration of the vasoactive medication and wherein the second dose of the NP is administered up to about 4 hours before the administration of the vasoactive medication and about 4 hours after administration of the vasoactive medication.

6. The method of claim 1 , wherein the dose of NP is sufficient to lower the systolic blood pressure of the patient by about 2 mm Hg to about 10 mm Hg.

7. The method of claim 1 , wherein the NP is administered in a dose range of about 1 ng/kg/min to about 5 ng/kg/min.

8. The method of claim 1 , wherein the NP is administered in a dose range of about 3 ng/kg/min to about 20 ng/kg/min.

Assignments (4)
CHANGE OF NAME Recorded Nov 4, 2014
From: NILE THERAPEUTICS, INC.
To: CAPRICOR THERAPEUTICS, INC.
Reel/Frame 034099/0847 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 21, 2014
From: MEDTRONIC, INC.
To: CAPRICOR THERAPEUTICS, INC.
Reel/Frame 033993/0025 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 27, 2012
From: VAN ANTWERP, WILLIAM P.
To: MEDTRONIC, INC.
Reel/Frame 029533/0944 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 23, 2012
From: EVANS, DARON; LIEU, HSIAO
To: NILE THERAPEUTICS, INC.
Reel/Frame 027920/0275 →
Continuity (3)
Provisional Application 61408320 · Oct 29, 2010
Provisional Application 61440154 · Feb 7, 2011
Related Publication 20120178689A1 · Jul 12, 2012